Furmonertinib plus radiation and chemo for EGFR lung cancer with brain spread
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of lung cancer called adenocarcinoma with an EGFR mutation (either 19Del or L858R).
- You have not had any prior treatment for advanced lung cancer (no chemo, targeted therapy, or immunotherapy).
- Your cancer has spread to both the brain tissue and the lining around the brain (leptomeninges).
- You are healthy enough for daily activities (ECOG score 0-2) and expected to live more than 12 weeks.
- Your kidney, liver, and blood counts must be within safe ranges (lab tests will confirm).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
This trial tests whether a targeted pill (furmonertinib) combined with local treatments like radiation or heat/cold to destroy the tumor can help people with early-stage lung cancer that has specific genetic changes (EGFR mutations). It aims to control the cancer without surgery.
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
This trial tests a combination of a targeted therapy (firmanertinib), a biologic drug that blocks blood vessel growth (bevacizumab), and a chemotherapy given into the spinal fluid (pemetrexed) for people with non-small cell lung cancer that has spread to the membranes around the brain (leptomeningeal metastasis). The goal is to see if this treatment helps control the cancer and improve symptoms.
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
This study tests two doses of furmonertinib (a targeted pill) combined with chemotherapy for people with a specific EGFR gene change in lung cancer that has spread to the brain. It aims to see if the higher dose works better while keeping side effects manageable.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.